AR123453A1 - Formulaciones de un modulador de somatostatina - Google Patents
Formulaciones de un modulador de somatostatinaInfo
- Publication number
- AR123453A1 AR123453A1 ARP210102492A ARP210102492A AR123453A1 AR 123453 A1 AR123453 A1 AR 123453A1 AR P210102492 A ARP210102492 A AR P210102492A AR P210102492 A ARP210102492 A AR P210102492A AR 123453 A1 AR123453 A1 AR 123453A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- hydroxybenzonitrile
- quinolin
- piperidin
- difluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076024P | 2020-09-09 | 2020-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123453A1 true AR123453A1 (es) | 2022-11-30 |
Family
ID=78078387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102492A AR123453A1 (es) | 2020-09-09 | 2021-09-08 | Formulaciones de un modulador de somatostatina |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11266641B1 (https=) |
| EP (2) | EP4210700B1 (https=) |
| JP (2) | JP7796115B2 (https=) |
| KR (1) | KR20230066379A (https=) |
| CN (2) | CN116456968B (https=) |
| AR (1) | AR123453A1 (https=) |
| AU (1) | AU2021341936A1 (https=) |
| CA (1) | CA3191084A1 (https=) |
| CL (1) | CL2023000627A1 (https=) |
| CO (1) | CO2023004346A2 (https=) |
| DK (1) | DK4210700T3 (https=) |
| ES (1) | ES3040117T3 (https=) |
| FI (1) | FI4210700T3 (https=) |
| HR (1) | HRP20250995T1 (https=) |
| IL (1) | IL301038A (https=) |
| LT (1) | LT4210700T (https=) |
| MA (1) | MA66139B1 (https=) |
| MD (1) | MD4210700T2 (https=) |
| MX (1) | MX2023002761A (https=) |
| PE (1) | PE20231850A1 (https=) |
| PL (1) | PL4210700T3 (https=) |
| PT (1) | PT4210700T (https=) |
| RS (1) | RS67208B1 (https=) |
| SI (1) | SI4210700T1 (https=) |
| SM (1) | SMT202500315T1 (https=) |
| WO (1) | WO2022055880A1 (https=) |
| ZA (1) | ZA202303250B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| WO2023137018A1 (en) * | 2022-01-11 | 2023-07-20 | Crinetics Pharmaceuticals, Inc. | Uses of a somatostatin modulator for the treatment of carcinoid syndrome |
| PE20260136A1 (es) * | 2022-05-11 | 2026-01-21 | Lilly Co Eli | Composiciones farmaceuticas de glp1 |
| CN115919866A (zh) * | 2022-12-07 | 2023-04-07 | 深圳海王医药科技研究院有限公司 | 特泊替尼固体分散体及其制备方法 |
| KR20250162795A (ko) | 2023-03-28 | 2025-11-19 | 크리네틱스 파마슈티칼스, 인크. | 간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법 |
| JP7797570B2 (ja) | 2023-05-23 | 2026-01-13 | ユルチョン・ケミカル・カンパニー・リミテッド | セルパウチ用フィルム及びその保管方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| CA2468159A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| WO2003066055A1 (en) | 2002-02-04 | 2003-08-14 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
| JP2008506695A (ja) | 2004-07-13 | 2008-03-06 | グラクソ グループ リミテッド | 抗細菌剤 |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| US7563821B2 (en) | 2005-12-05 | 2009-07-21 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| WO2007103554A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| AU2007309708A1 (en) | 2006-03-13 | 2008-05-02 | Merck Sharp & Dohme Corp. | Somatostatin agonists |
| US8871728B2 (en) | 2007-06-29 | 2014-10-28 | Georgia Tech Research Corporation | Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof |
| HRP20180328T1 (hr) * | 2008-08-13 | 2018-04-20 | Vertex Pharmaceuticals Inc. | FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| JP5564045B2 (ja) | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| CA2806332C (en) | 2010-07-30 | 2017-11-14 | Oncotherapy Science, Inc. | Quinoline derivatives and melk inhibitors containing the same |
| RU2013113627A (ru) * | 2010-08-27 | 2014-10-10 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| RU2637936C2 (ru) | 2011-05-23 | 2017-12-08 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
| WO2012163354A1 (en) | 2011-05-31 | 2012-12-06 | Linak A/S | Actuator |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| DE102011113749A1 (de) | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
| US20140228417A1 (en) | 2011-10-05 | 2014-08-14 | Mapi Pharma Ltd. | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| KR20150039832A (ko) | 2012-08-06 | 2015-04-13 | 사피라 파르마슈티칼즈 게엠베하 | 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도 |
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| CN105073729A (zh) | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
| WO2014114575A1 (en) | 2013-01-22 | 2014-07-31 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| US10647664B2 (en) | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
| US9643951B2 (en) | 2013-09-30 | 2017-05-09 | Ono Pharmaceutical Co., Ltd. | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| JPWO2015146929A1 (ja) | 2014-03-24 | 2017-04-13 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| EP3317278B1 (en) | 2015-07-01 | 2021-04-14 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| RS61645B1 (sr) | 2015-10-30 | 2021-04-29 | Neurocrine Biosciences Inc | Valbenazin ditozilat i njihovi polimorfi |
| EP3374350B1 (en) | 2015-11-09 | 2022-01-05 | Forge Therapeutics, Inc. | Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| MX2019000246A (es) | 2016-07-07 | 2019-05-27 | Plantex Ltd | Formas en estado solido del dimesilato de palbociclib. |
| IL264178B2 (en) | 2016-07-14 | 2024-05-01 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| EP3596062A4 (en) | 2017-03-16 | 2020-08-26 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND THEIR USES |
| WO2018208987A2 (en) | 2017-05-10 | 2018-11-15 | Forge Therapeutics, Inc. | Antibacterial compounds |
| CN110913840A (zh) | 2017-08-11 | 2020-03-24 | 默克专利股份公司 | 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂 |
| PT3740475T (pt) | 2018-01-17 | 2022-07-18 | Crinetics Pharmaceuticals Inc | Processo de produção de moduladores da somatostatina |
| SMT202500155T1 (it) | 2018-09-18 | 2025-05-12 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
| JP2022540922A (ja) * | 2019-07-17 | 2022-09-20 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| BR112023024465A2 (pt) | 2021-05-25 | 2024-02-06 | Crinetics Pharmaceuticals Inc | Usos de um modulador de somatostatina para o tratamento de doença |
| CN117377473A (zh) * | 2021-05-25 | 2024-01-09 | 克林提克斯医药股份有限公司 | 生长抑素调节剂用于治疗疾病的用途 |
-
2021
- 2021-09-07 CA CA3191084A patent/CA3191084A1/en active Pending
- 2021-09-07 EP EP21786673.0A patent/EP4210700B1/en active Active
- 2021-09-07 MD MDE20230709T patent/MD4210700T2/ro unknown
- 2021-09-07 DK DK21786673.0T patent/DK4210700T3/da active
- 2021-09-07 EP EP25185699.3A patent/EP4635497A3/en active Pending
- 2021-09-07 PL PL21786673.0T patent/PL4210700T3/pl unknown
- 2021-09-07 ES ES21786673T patent/ES3040117T3/es active Active
- 2021-09-07 SM SM20250315T patent/SMT202500315T1/it unknown
- 2021-09-07 CN CN202180068588.2A patent/CN116456968B/zh active Active
- 2021-09-07 FI FIEP21786673.0T patent/FI4210700T3/fi active
- 2021-09-07 SI SI202130344T patent/SI4210700T1/sl unknown
- 2021-09-07 RS RS20250820A patent/RS67208B1/sr unknown
- 2021-09-07 PE PE2023000942A patent/PE20231850A1/es unknown
- 2021-09-07 IL IL301038A patent/IL301038A/en unknown
- 2021-09-07 CN CN202610102122.4A patent/CN121943816A/zh active Pending
- 2021-09-07 KR KR1020237011002A patent/KR20230066379A/ko active Pending
- 2021-09-07 MA MA66139A patent/MA66139B1/fr unknown
- 2021-09-07 PT PT217866730T patent/PT4210700T/pt unknown
- 2021-09-07 LT LTEPPCT/US2021/049282T patent/LT4210700T/lt unknown
- 2021-09-07 MX MX2023002761A patent/MX2023002761A/es unknown
- 2021-09-07 AU AU2021341936A patent/AU2021341936A1/en active Pending
- 2021-09-07 US US17/468,440 patent/US11266641B1/en active Active
- 2021-09-07 HR HRP20250995TT patent/HRP20250995T1/hr unknown
- 2021-09-07 WO PCT/US2021/049282 patent/WO2022055880A1/en not_active Ceased
- 2021-09-07 JP JP2023515559A patent/JP7796115B2/ja active Active
- 2021-09-08 AR ARP210102492A patent/AR123453A1/es unknown
-
2022
- 2022-01-25 US US17/584,225 patent/US11957674B2/en active Active
-
2023
- 2023-03-01 ZA ZA2023/03250A patent/ZA202303250B/en unknown
- 2023-03-03 CL CL2023000627A patent/CL2023000627A1/es unknown
- 2023-04-04 CO CONC2023/0004346A patent/CO2023004346A2/es unknown
-
2024
- 2024-03-08 US US18/599,998 patent/US20240398782A1/en active Pending
-
2025
- 2025-12-19 JP JP2025269820A patent/JP2026067866A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123453A1 (es) | Formulaciones de un modulador de somatostatina | |
| SI2942051T1 (en) | A solid pharmaceutical dosage form comprising a solid dispersion of an HIV protease inhibitor | |
| CL2004000270A1 (es) | Compuestos derivados de pirazol, sus sales de adicion acidas,trastornos de vih y virus geneticamente relacionados. hidratos, solvatos; composiciones farmaceuticas; y su uso en el tramiento de trastornos del vih y virus geneticamente relacionados. | |
| AR048596A1 (es) | Atenuacion sinergica del virus de estomatitis vesiculosa, sus vectores y sus composiciones inmunogenas | |
| MX2020003337A (es) | Copolimeros de olefinas halogenadas y co-monomeros halogenados. | |
| PH12022550083A1 (en) | Cardiac sarcomere inhibitor oral formulations | |
| EP4056558A4 (en) | INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF | |
| ATE441000T1 (de) | Zusammensetzungen optischer aufheller | |
| PH12021551082A1 (en) | Crosslinked artificial nucleic acid alna | |
| GEAP202516730A (en) | Modulators of alpha-i antitrypsin | |
| JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| CO5280222A1 (es) | Composicion farmaceutica que comprende pemetrexed | |
| BR112022008384A2 (pt) | Formulação oral de x842 | |
| Yazdan Parast et al. | Viscous loading regulates the flagellar energetics of human and bull sperm | |
| MY197663A (en) | Pharmaceutical formulation | |
| EP3969070A4 (en) | POLYMER-BASED RETINA THERAPY IMPLANT AND METHOD OF MAKING AND USE THEREOF | |
| JP1737528S (ja) | 焚き火台用装置 | |
| AR108972A1 (es) | Tratamiento de la enfermedad vascular retiniana mediante el uso de células progenitoras | |
| PH12022550316A1 (en) | An oral care spray composition comprising hexametaphosphate | |
| MX2021013137A (es) | Composicion del cuidado oral. | |
| MX2021006693A (es) | Fórmula de entrega de medicamentos colónicos. | |
| MX2024008598A (es) | Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide. | |
| WO2021080931A8 (en) | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use | |
| PE20240021A1 (es) | Dispersiones solidas amorfas | |
| MX2021012320A (es) | Composiciones farmaceuticas solidas para el tratamiento del hcv. |